Please use this identifier to cite or link to this item:
http://hdl.handle.net/11452/30124
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.date.accessioned | 2022-12-28T06:36:46Z | - |
dc.date.available | 2022-12-28T06:36:46Z | - |
dc.date.issued | 2017-02-23 | - |
dc.identifier.citation | Yılmazlar, T. vd. (2017). ''Microbiological aspects of Fournier's gangrene''. International Journal of Surgery, 40, 135-138. | en_US |
dc.identifier.issn | 1743-9191 | - |
dc.identifier.uri | https://doi.org/10.1016/j.ijsu.2017.02.067 | - |
dc.identifier.uri | https://www.sciencedirect.com/science/article/pii/S1743919117301929 | - |
dc.identifier.uri | 1743-9159 | - |
dc.identifier.uri | http://hdl.handle.net/11452/30124 | - |
dc.description.abstract | Background: Fournier's gangrene (FG) is a devastating disease that is characterized by necrotizing fasciitis of the perineal, genital, or perianal region. Broad-spectrum antibiotics are the key component of its treatment. However, there is paucity of data regarding the optimal empirical antibiotherapy for FG. Materials and methods: Data from patients who underwent surgery for FG between January 2007 and December 2012 were retrieved from a prospectively collected departmental FG database. Demographics, clinical characteristics, causative pathogens and drug susceptibility/resistance were evaluated. Results: Fifty patients with a median age of 58.5 (22-83) years were included. The perianal origin (58%) was most commonly affected. A positive growth was found in specimen cultures of 48 (96%) patients. The median number of bacterial strains that grew in the cultures was 3 (0-10). Amikacin was the antibiotic with the highest frequency of sensitivity (74%), while the highest resistance was observed against ampicillin-sulbactam (64%). Escherichia coli was the most common microorganism (72%). Acinetobacter baumannii and Klebsiella pneumonia were significantly more common in patients who required mechanical ventilation. The mortality rate was 26%. An Uludag Fournier's Gangrene Severity Index (UFGSI) score of >9.5 and ventilatory support requirement were factors associated with an increased rate of mortality. Acinetobacter baumannii was the only microorganism which was associated with an increased mortality rate. Conclusion: Causative pathogens in FG appeared to be shifting; thus, empirical antibiotic treatment for this disease should be modified. We recommend 3rd-generation cephalosporin, metronidazole and amikacin for empirical therapy. | en_US |
dc.language.iso | en | en_US |
dc.publisher | Elsevier | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.rights | Atıf Gayri Ticari Türetilemez 4.0 Uluslararası | tr_TR |
dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/4.0/ | * |
dc.subject | Surgery | en_US |
dc.subject | Empiric antimicrobial therapy | en_US |
dc.subject | Microbial | en_US |
dc.subject | Necrotizing fasciitis | en_US |
dc.subject | Ventilator-associated pneumonia | en_US |
dc.subject | Predictors | en_US |
dc.subject | Management | en_US |
dc.subject | Mortality | en_US |
dc.subject.mesh | Adult | en_US |
dc.subject.mesh | Aged | en_US |
dc.subject.mesh | Aged, 80 and over | en_US |
dc.subject.mesh | Anti-bacterial agents | en_US |
dc.subject.mesh | Female | en_US |
dc.subject.mesh | Fournier gangrene | en_US |
dc.subject.mesh | Humans | en_US |
dc.subject.mesh | Male | en_US |
dc.subject.mesh | Microbial sensitivity tests | en_US |
dc.subject.mesh | Middle aged | en_US |
dc.subject.mesh | Prospective studies | en_US |
dc.title | Microbiological aspects of Fournier's gangrene | en_US |
dc.type | Article | en_US |
dc.identifier.wos | 000402486400022 | tr_TR |
dc.identifier.scopus | 2-s2.0-85014506784 | tr_TR |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | tr_TR |
dc.contributor.department | Uludağ Üniversitesi/Tıp Fakültesi/Cerrahi Anabilim Dalı. | tr_TR |
dc.contributor.orcid | 0000-0002-9541-5035 | tr_TR |
dc.identifier.startpage | 135 | tr_TR |
dc.identifier.endpage | 138 | tr_TR |
dc.identifier.volume | 40 | tr_TR |
dc.relation.journal | International Journal of Surgery | en_US |
dc.contributor.buuauthor | Yılmaz, Tuncay | - |
dc.contributor.buuauthor | Gülcü, Barış | - |
dc.contributor.buuauthor | Öztürk, Ersin | - |
dc.contributor.buuauthor | Işık, Özgen | - |
dc.contributor.researcherid | AAW-9602-2020 | tr_TR |
dc.contributor.researcherid | P-5779-2019 | tr_TR |
dc.contributor.researcherid | ABH-2238-2021 | tr_TR |
dc.identifier.pubmed | 28257985 | tr_TR |
dc.subject.wos | Surgery | en_US |
dc.indexed.wos | SCIE | en_US |
dc.indexed.scopus | Scopus | en_US |
dc.indexed.pubmed | PubMed | en_US |
dc.wos.quartile | Q2 | en_US |
dc.contributor.scopusid | 6701800362 | tr_TR |
dc.contributor.scopusid | 56618783200 | tr_TR |
dc.contributor.scopusid | 36600543700 | tr_TR |
dc.contributor.scopusid | 35070171400 | tr_TR |
dc.subject.scopus | Fournier Gangrene; Bouteloua; Necrotizing Fasciitis | en_US |
dc.subject.emtree | Amikacin | en_US |
dc.subject.emtree | Cefazolin | en_US |
dc.subject.emtree | Cefepime | en_US |
dc.subject.emtree | Cephalosporin | en_US |
dc.subject.emtree | Ciprofloxacin | en_US |
dc.subject.emtree | Colistin | en_US |
dc.subject.emtree | Daptomycin | en_US |
dc.subject.emtree | Gentamicin | en_US |
dc.subject.emtree | Imipenem | en_US |
dc.subject.emtree | Levofloxacin | en_US |
dc.subject.emtree | Meropenem | en_US |
dc.subject.emtree | Metronidazole | en_US |
dc.subject.emtree | Moxifloxacin | en_US |
dc.subject.emtree | Piperacillin plus tazobactam | en_US |
dc.subject.emtree | Sultamicillin | en_US |
dc.subject.emtree | Teicoplanin | en_US |
dc.subject.emtree | Vancomycin | en_US |
dc.subject.emtree | Antiinfective agent | en_US |
dc.subject.emtree | Acinetobacter baumannii | en_US |
dc.subject.emtree | Adult | en_US |
dc.subject.emtree | Aged | en_US |
dc.subject.emtree | Antibiotic resistance | en_US |
dc.subject.emtree | Antibiotic sensitivity | en_US |
dc.subject.emtree | Article | en_US |
dc.subject.emtree | Artificial ventilation | en_US |
dc.subject.emtree | Bacterial growth | en_US |
dc.subject.emtree | Bacterium culture | en_US |
dc.subject.emtree | Burkholderia gladioli | en_US |
dc.subject.emtree | Citrobacter | en_US |
dc.subject.emtree | Clinical article | en_US |
dc.subject.emtree | Corynebacterium | en_US |
dc.subject.emtree | Disease severity assessment | en_US |
dc.subject.emtree | Enterococcus | en_US |
dc.subject.emtree | Escherichia coli | en_US |
dc.subject.emtree | Fournier gangrene | en_US |
dc.subject.emtree | Human | en_US |
dc.subject.emtree | Human tissue | en_US |
dc.subject.emtree | Klebsiella pneumoniae | en_US |
dc.subject.emtree | Male | en_US |
dc.subject.emtree | Methicillin-resistant staphylococcus epidermidis | en_US |
dc.subject.emtree | Morganella morganii | en_US |
dc.subject.emtree | Mortality rate | en_US |
dc.subject.emtree | Nonhuman | en_US |
dc.subject.emtree | Priority journal | en_US |
dc.subject.emtree | Pseudomonas aeruginosa | en_US |
dc.subject.emtree | Serratia | en_US |
dc.subject.emtree | Staphylococcus aureus | en_US |
dc.subject.emtree | Streptococcus anginosus | en_US |
dc.subject.emtree | Fournier gangrene | en_US |
dc.subject.emtree | Microbial sensitivity test | en_US |
dc.subject.emtree | Microbiology | en_US |
dc.subject.emtree | Middle aged | en_US |
dc.subject.emtree | Prospective study | en_US |
dc.subject.emtree | Very elderly | en_US |
dc.subject.emtree | Female | en_US |
Appears in Collections: | Scopus Web of Science |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Yılmazlar_vd_2017.pdf | 198.79 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License